论文部分内容阅读
我们用随机抽样法选择病例,研究葛根素治疗冠心病的临(?)价值。冠心病人46例,分为葛根素加肝素治疗组31例,单纯肝素治疗组15例。结果显示:葛根素组治疗后病人心率、血压、心肌耗氧指数、血液粘度均较用药前(?)显降低,其中心率及心肌耗氧指数、血液粘度较对照组明显降低,差异显著(P<0.05～0.01)。葛根素治疗组病人心绞痛发作频率、持续时间、硝酸甘油消耗量及心电图改善总有效率均较对照组明显改善(P<0.05);心律失常、梗塞面积扩大及住院病死率均较对照组显著降低(P<0.05)。表明:葛根素具有抗心肌梗塞、抗心肌缺血、抗高血压、抗心律失常作用,是治疗冠心病安全、有效的药物。
We selected cases by random sampling to study the clinical value of puerarin in the treatment of coronary heart disease. 46 cases of coronary heart disease, divided into puerarin plus heparin treatment group of 31 cases, heparin alone treatment group of 15 cases. The results showed that the heart rate, blood pressure, myocardial oxygen consumption index and blood viscosity of the puerarin group were significantly lower than those before treatment (P <0.05), and their heart rate, myocardial oxygen consumption index and blood viscosity were significantly lower than those of the control group <0.05 ~ 0.01). The incidence of angina pectoris, duration, the consumption of nitroglycerin and the total effective rate of ECG in the puerarin-treated group were significantly improved compared with the control group (P <0.05); arrhythmia, infarct size and hospital mortality were significantly lower than those in the control group (P <0.05). It shows that puerarin has anti-myocardial infarction, anti-myocardial ischemia, antihypertensive and anti-arrhythmic effects and is a safe and effective drug for the treatment of coronary heart disease.